Percent free prostate-specific antigen after radiotherapy for prostate cancer - 8 to 10 ng/mL total PSA

By Crook J.M.   Bunting P.S.  

Urology, Vol. 52, Iss. 1, 1998-07 ,pp. : 100-105

Elsevier

Access to resources Recommend Favorite

What does postradiotherapy PSA nadir tell us about freedom from PSA failure and progression-free survival in patients with low and intermediate-risk localized prostate cancer?

By DeWitt K.D.   Sandler H.M.   Weinberg V.   McLaughlin P.W.   Roach M.  

Urology, Vol. 62, Iss. 3, 2003-09 ,pp. : 492-496

Elsevier

Access to resources Recommend Favorite

Post-treatment PSA =<0.2 ng/ml defines disease freedom after radiotherapy for prostate cancer using modern techniques - 5-year tumor control and morbidity

By Critz F.A.   Williams W.H.   Holladay C.T.   Levinson A.K.   Benton J.B.   Holladay D.A.   Schnell F.J.   Maxa L.S.   Shrake P.D.  

Urology, Vol. 54, Iss. 6, 1999-12 ,pp. : 968-971

Elsevier

Access to resources Recommend Favorite

RT-PCR for PSA as a prognostic factor for patients with clinically localized prostate cancer treated with radiotherapy

By Gewanter R.M.   Katz A.E.   Olsson C.A.   Benson M.C.   Singh A.   Schiff P.B.   Ennis R.D.  

Urology, Vol. 61, Iss. 5, 2003-05 ,pp. : 967-971

Elsevier

Access to resources Recommend Favorite

PSA-based outcome analysis after radiation therapy for prostate cancer: a new definition of biochemical failure after intervention

By Jani A.B.   Chen M.-H.   Vaida F.   Ignacio L.   Awan A.   Weichselbaum R.R.   Vijayakumar S.  

Urology, Vol. 54, Iss. 4, 1999-10 ,pp. : 700-705

Elsevier

Access to resources Recommend Favorite